Genomics studies aim to improve targeted therapies

June 27, 2017

Two studies at Providence Cancer Institute are focusing on patients’ genomes to help identify the most effective targeted anti-cancer therapies:

TriSeq Study:

The TriSeq study uses genetic sequencing to better understand the effects of patients’ genomes on their response to immunotherapy, and to identify tumor-specific molecules that hold the potential to be targeted with immunotherapy. The study involves sequencing a patient's tumor exome (the coding regions of the genome), transcriptome (to determine whether genes are switched "on" or "off"), and germline exome (to find inherited mutations in the genome). Using new computational approaches, researchers will mine the patient’s genome for neoantigens – molecular differences between tumor cells and normal cells that can be targeted by immunotherapies.  

Participating patients will receive a clinical case workup through the Providence Personalized Medicine Panel (PPMP). The PPMP is a large (300+ genes) sequencing test for solid tumors and hematologic malignancies. It helps identify treatments (both FDA approved and those still in clinical trials) that may be beneficial to patients based on their cancer's genetic mutations.

TAPUR (Targeted Agent and Profiling Utilization Registry) study:

The TAPUR study aims to define the safety and efficacy of commercially available, targeted anti-cancer drugs prescribed for patients who have advanced cancers with genomic mutations that can be targeted with drugs. This non-randomized clinical trial will study FDA-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the molecular profiling tests chosen by clinical oncologists, and develop hypotheses for additional clinical trials. Read more about TAPUR, and see the TAPUR enrollment criteria.

Read more about whole-genome sequencing at Providence.

To refer patients to either of these studies, call Providence Cancer Institute’s Clinical Trials office at 503-215-2614 or visit

See a list of more than 160 open studies in all cancer types at Providence Cancer Institute.